![John Herbert Alcock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Herbert Alcock
Director/Miembro de la Junta en North West Lung Centre .
Origen de la red de primer grado John Herbert Alcock.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
North West Lung Centre
![]() North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities.
8
| Non-Profit Organization | Medical/Nursing Services | 8 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a John Herbert Alcock a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
The Medicines Evaluation Unit Ltd.
![]() The Medicines Evaluation Unit Ltd. Miscellaneous Commercial ServicesCommercial Services The Medicines Evaluation Unit Ltd. offers clinical trial solutions. It provides clinical trials and early phase exploratory studies in the pharmaceutical, scientific and clinical sectors. The firm specializes in performing clinical trials in respiratory and inflammatory medicine and related areas as well as conducting healthy volunteer, bioequivalence and SAD/MAD studies. The company is headquartered in Manchester, the United Kingdom. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Reacta Biotech Ltd.
![]() Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | Miscellaneous Commercial Services | Founder | |
Axalbion SA | Chairman | ||
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Biotechnology | Chairman |
Estadísticas
Internacional
Reino Unido | 4 |
Suiza | 2 |
Sectorial
Commercial Services | 3 |
Health Technology | 2 |
Operativa
Director/Board Member | 9 |
Chairman | 4 |
Founder | 1 |
Las relaciones más conectadas
- Bolsa de valores
- Insiders
- John Herbert Alcock
- Conexiones Empresas